Hemophilia A: all 885 studies

Page 9 of 9. Open to participants first (139), then studies with results posted, then the rest; newest registration first within each.

• Individually Tailored Prophylaxis in Patients With Severe Hemophilia ATerminatedNCT00995046Not applicable
• Comparison of Two Types of Ankle Braces in the Management of Ankle Pain in HemophiliaCompletedNCT00972296
• Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin AmericaCompletedNCT00969319
• Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia BCompletedNCT00956345Phase 1
• A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male VolunteersCompletedNCT00951873Phase 1
• Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With InhibitorsCompletedNCT00951405Phase 2
• Females With Severe or Moderate Hemophilia A or B: A Multi-Center StudyCompletedNCT00936845
• Females With Severe or Moderate Hemophilia A or B: an International Multi-center StudyCompletedNCT00936312
• EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in TaiwanCompletedNCT00932555
• Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment RegimensCompletedNCT00927667Phase 4
• Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and BCompletedNCT00922792Phase 1
• Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in SurgeryCompletedNCT00922597
• Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia ACompletedNCT00879541Phase 2
• EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FSCompletedNCT00874926
• International PMS Study - KOGENATE BayerCompletedNCT00864552
• Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia DatabaseCompletedNCT00853086
• Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel ImmunoassayCompletedNCT00839202Not applicable
• Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A SubjectsCompletedNCT00837356Phase 1
• Gait Evaluation in Haemophiliac PatientsCompletedNCT00824798
• A Feasibility Study to Collect Data in Patients With HaemophiliaCompletedNCT00798499
• Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With HemophiliaStatus unknownNCT00797381
• Phase I/IIa Study of FIXFc in Hemophilia B PatientsCompletedNCT00716716Phase 1
• Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IXCompletedNCT00710619
• Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus InfectionCompletedNCT00707772Phase 4
• The Use of Cyclokapron for Treatment and Management of Women With Bleeding DisordersCompletedNCT00697385Not applicable
• Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in GermanyCompletedNCT00697320
• Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle ArthropathyCompletedNCT00638001Phase 4
• Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980CompletedNCT00629837Phase 1
• Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia ATerminatedNCT00621673Phase 4
• BAY14-2222 Continuous Infusion in SurgeriesCompletedNCT00606060Phase 3
• Study Evaluating Approach to Treatment of Haemophilia A and B in SpainCompletedNCT00581438
• Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia BCompletedNCT00581126Phase 4
• High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With InhibitorsCompletedNCT00571584Phase 4
• LTFU for Gene Transfer Subjects With Hemophilia BCompletedNCT00515710
• Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation ActivationCompletedNCT00375323Phase 3
• Genetic Susceptibility to Factor VIII InhibitorsCompletedNCT00344435
• The Second Multicenter Hemophilia Cohort StudyCompletedNCT00341705
• Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)TerminatedNCT00340548
• Musculoskeletal Function in HemophiliaStatus unknownNCT00324493
• Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIIICompletedNCT00284193Phase 4
• The Influence of "Karate" on Bleeding in Hemophilic Patients.TerminatedNCT00281333Not applicable
• Clot Formation and Clot Stability in Patients With Severe Haemophilia ACompletedNCT00279578Not applicable
• Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.CompletedNCT00245297Phase 2
• Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIIICompletedNCT00245245Phase 2
• Study Evaluating Allergic Reactions To Benefix In Hemophilia B PatientsCompletedNCT00244114
• The Malmö International Brother Study (MIBS)CompletedNCT00231751
• ADVATE Post Authorization Safety SurveillanceCompletedNCT00214734
• Prospective Clinical and Biological Follow-up of Acquired Haemophilia : SACHA StudyCompletedNCT00213473
• International Immune Tolerance StudyTerminatedNCT00212472Not applicable
• The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding LogsCompletedNCT00212459Not applicable
• Joint Outcome StudyCompletedNCT00207597
• Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia BCompletedNCT00195221
• Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101CompletedNCT00189982Phase 2/3
• Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in HemophiliaCompletedNCT00178607
• Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)CompletedNCT00168090Phase 4
• Study Comparing Blood Levels of ReFacto and Advante in Hemophilia AWithdrawnNCT00168051Phase 4
• Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual UseCompletedNCT00167973
• Hemophilia Inhibitor Genetics Study (HIGS)CompletedNCT00166387
• The FEIBA NovoSeven Comparative StudyCompletedNCT00166309Not applicable
• Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A PatientsCompletedNCT00162019Phase 3
• Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing SurgeryCompletedNCT00157105Phase 2/3
• Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901CompletedNCT00157053Phase 2/3
• Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia ACompletedNCT00157040Phase 2/3
• Study Evaluating Inhibitor Specificity in Hemophilia AWithdrawnNCT00151385Phase 4
• Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia ACompletedNCT00141843Phase 3
• Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)CompletedNCT00139828Phase 4
• Trial of NovoSeven® in Haemophilia - Joint BleedsCompletedNCT00108797Phase 4
• Efficacy of NovoSeven® in Bleeding Prophylaxis in HemophiliaCompletedNCT00108758Phase 2
• Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia BCompletedNCT00093210Phase 3
• Study Evaluating rFIX; BeneFIX® in Hemophilia BCompletedNCT00093171Phase 3
• Study Evaluating ReFacto® in Hemophilia A Undergoing Major SurgeryCompletedNCT00092976Phase 4
• Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia BTerminatedNCT00076557Phase 1/2
• Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia ACompletedNCT00038935Phase 3
• Study Evaluating ReFacto in Hemophilia ACompletedNCT00038909Not applicable
• Study Evaluating rFIX; BeneFIX in Severe Hemophilia BCompletedNCT00037557Phase 3
• Study Evaluating ReFacto AF in Severe Hemophilia ACompletedNCT00037544Phase 3
• Hepatitis C in Clinically Discordant Hemophilic SiblingsCompletedNCT00007371
• Epidemiology and Immunology of Hemophilia A InhibitorsCompletedNCT00005518
• Prospective Study of HIV Infection in HemophiliacsCompletedNCT00005309
• Hepatitis Delta Infections in HemophiliacsCompletedNCT00005305
• Delta Hepatitis and Liver Disease in HemophiliacsCompletedNCT00005304
• Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With HemophiliaCompletedNCT00002386Phase 4
• The Effects of AZT and Ibuprofen on HIV-Infected Patients With HemophiliaCompletedNCT00002276Not applicable
• Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With HemophiliaCompletedNCT00000705Phase 1
• Cooperative Study of Factor VIII InhibitorsCompletedNCT00000582Phase 3

← Hemophilia A overview